Flecainide hydrochloride, an antiarrhythmic drug, is a blocker of hydrophilic sodium channels with a pKa of 9.3. At pH 7.4. It also inhibits the ryanodine receptor (RyR2), reducing spontaneous calcium release from the sarcoplasmic reticulum.

Flecainide hydrochloride, an antiarrhythmic drug, is a blocker of hydrophilic sodium channels with a pKa of 9.3. At pH 7.4. It also inhibits the ryanodine receptor (RyR2), reducing spontaneous calcium release from the sarcoplasmic reticulum.

Flecainide hydrochloride, an antiarrhythmic drug, is a blocker of hydrophilic sodium channels with a pKa of 9.3. At pH 7.4. It also inhibits the ryanodine receptor (RyR2), reducing spontaneous calcium release from the sarcoplasmic reticulum.

Formoterol is a highly selective and potent long-acting beta2-adrenergic agonist that functions by binding to and activating beta2-adrenergic receptors on the smooth muscle cells of the airways. It is used in the treatment of patients with chronic obstructive pulmonary disease (COPD).

Formoterol is a highly selective and potent long-acting beta2-adrenergic agonist that functions by binding to and activating beta2-adrenergic receptors on the smooth muscle cells of the airways. It is used in the treatment of patients with chronic obstructive pulmonary disease (COPD).

Flecainide hydrochloride, an antiarrhythmic drug, is a blocker of hydrophilic sodium channels with a pKa of 9.3. At pH 7.4. It also inhibits the ryanodine receptor (RyR2), reducing spontaneous calcium release from the sarcoplasmic reticulum.

Formoterol is a highly selective and potent long-acting beta2-adrenergic agonist that functions by binding to and activating beta2-adrenergic receptors on the smooth muscle cells of the airways. It is used in the treatment of patients with chronic obstructive pulmonary disease (COPD).

Formoterol is a highly selective and potent long-acting beta2-adrenergic agonist that functions by binding to and activating beta2-adrenergic receptors on the smooth muscle cells of the airways. It is used in the treatment of patients with chronic obstructive pulmonary disease (COPD).

Fostemsavir Tris(BMS-663068 Tris) is a phosphonooxymethyl prodrug of BMS-626529, formulated as a tris(hydroxymethyl)aminomethane salt. It inhibits human immunodeficiency virus type 1 (HIV-1) by binding to the gp120 protein, preventing the virus from attaching to CD4+ T-cells.

Fostemsavir Tris(BMS-663068 Tris) is a phosphonooxymethyl prodrug of BMS-626529, formulated as a tris(hydroxymethyl)aminomethane salt. It inhibits human immunodeficiency virus type 1 (HIV-1) by binding to the gp120 protein, preventing the virus from attaching to CD4+ T-cells.